Weight management
RTTA
The strongest of the appetite and fat-metabolism peptides
Lab tested
Tested independently by Janoshik Analytical. Open the report to see the full result.
Strength
Format
Add a refill for your pen
RTTA 10 mg · +AED 540 each
Quantity — buy more, save more
Other quantity
Any mix counts: items from other products add up too.
Frequently paired with
Tap Add — each one counts toward your bundle saving.
MOTS-c 40 mg
AED 1180
Also in a bundle: Metabolic pair
Add another item from the catalogue
Pens are added as the reusable pen; change the format on the product page if you prefer.
A triple-agonist peptide studied for its action on the GLP-1, GIP and glucagon receptors — three of the signals involved in appetite and energy balance. Research interest centres on appetite regulation and how the body handles stored and visceral fat.
Research use only. Supplied for laboratory and analytical research. Not a medicine or supplement, and not for human or animal use. We don't give dosing or clinical advice. Read the terms
- Presentation
- Lyophilised, reconstituted — 3 mL pen
Manufactured under controlled research-grade conditions. For documentation or questions about this compound, contact us on WhatsApp.
Published research
- Human trial
In a 48-week phase 2 trial in adults with obesity or overweight, RTTA produced dose-dependent reductions in body weight compared with placebo.
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England Journal of Medicine. 2023. PMID 37366315
- Human trial
In a phase 2 trial of 281 adults with type 2 diabetes, once-weekly RTTA lowered HbA1c more than placebo at all but the lowest dose and reduced body weight dose-dependently over 36 weeks; mild-to-moderate gastrointestinal side effects were reported.
Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. PMID 37385280
- Human trial
In a phase 2a substudy of adults with obesity and fatty liver disease, RTTA reduced liver fat substantially more than placebo at 24 weeks.
Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024. PMID 38858523
- Review
This review describes RTTA as an investigational GIP, GLP-1 and glucagon receptor agonist, cites a phase 2 obesity trial reporting average weight loss of 24.4% at 48 weeks, and notes that phase 3 evidence is still needed.
Kaur M, et al. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. European Journal of Clinical Pharmacology. 2024. PMID 38367045
Short summaries of published studies, with links to the original papers. Results in animals or cells may not apply to people. This is not medical advice and not a guide to use.